Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.020
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
What's Going On With VistaGen Therapeutics Stock?
August 08, 2023
VistaGen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 09, 2023
Via
Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
August 09, 2023
Via
Investor Brand Network
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 08, 2023
From
Vistagen
Via
Business Wire
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7
August 07, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 08, 2023
Via
Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 08, 2023
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 08, 2023
Via
Benzinga
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
August 07, 2023
Vistagen Therapeutics has reported positive Phase 3 trial results for a social anxiety treatment. VTGN stock is skyrocketing as a result.
Via
InvestorPlace
Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
August 07, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
August 07, 2023
Via
Benzinga
Crude Oil Down Over 1%; Henry Schein Earnings Top Views
August 07, 2023
U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,...
Via
Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 07, 2023
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder
August 07, 2023
Via
Investor Brand Network
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
August 07, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results
August 07, 2023
U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to...
Via
Benzinga
Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
August 07, 2023
Vistagen Therapeutics Inc (NASDAQ: VTGN) released topline results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 07, 2023
Via
Benzinga
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 07, 2023
From
Vistagen
Via
Business Wire
VistaGen's New Preclinical Depression Treatment Study: Itruvone Nasal Spray Limits Systemic Exposure, Shows Promise
July 17, 2023
Vistagen Inc (NASDAQ: VTGN) revealed a new mechanism of action data from a preclinical tissue distribution
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
July 17, 2023
Via
Investor Brand Network
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 17, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
July 14, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
July 13, 2023
From
Vistagen
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
July 07, 2023
Via
Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
June 29, 2023
Via
Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
June 28, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
June 28, 2023
Via
Investor Brand Network
Earnings Scheduled For June 28, 2023
June 28, 2023
Companies Reporting Before The Bell • General Mills (NYSE:GIS) is estimated to report quarterly earnings at $1.07 per share on revenue of $5.17 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.